Wendelsheim (Germany) – Ehrfeld Mikrotechnik BTS GmbH (EMB), a subsidiary of Bayer Technology Services GmbH, has acquired a worldwide license from Alfa Laval to market and manufacture ART® reactor technology. With these millistructured plate reactors, which are used in laboratory, pilot and production plants, EMB is now the leading supplier of metal micro- and millistructured reactors and apparatus.

“The ART® reactor technology from Alfa Laval enables us to ideally round out our portfolio of innovative, robust plate reactors for production use,” said EMB Managing Director Dr. Joachim Heck. “Their high performance really shines when it comes to fast and extremely exothermic or endothermic – and thus very demanding – reactions.”

Micro- and millireactor technology offers substantial advantages over batch and other reactors, particularly in the pharmaceutical industry as well as in the fine and specialty chemicals industries. In addition to numerous other aspects, the outstanding heat transfer and simple scale-up provide advantage for process intensification with respect to yield, costs and safety. “Ehrfeld Mikrotechnik BTS is a highly-qualified and experienced partner that will hold the exclusive rights to our ART® reactor technology in the future. We secure that our customers will continue to be served with proven technology and expert knowledge,” said Alex Syed, Vice President and Head of Alfa Laval´s Corporate Development, underscoring the importance of the transaction. “We are pleased that we were able to enter into a license agreement with such a prominent company as Alfa Laval, which has for decades been among the best in the world for heat transfer, mixing, separation and continuous fluid handling technologies,” said Heck at contract signing.

About Ehrfeld Mikrotechnik BTS

Ehrfeld Mikrotechnik BTS GmbH is a subsidiary of Bayer Technology Services GmbH and a leading supplier of microreaction technology products such as micro and milli reactors, heat exchangers and related devices for lab and production units. With its product platforms modular MicroReactionSystems (MMRS), Lonza FlowPlate® micro reactors, Miprowa® high efficiency reactors and heat exchangers as well as the newly acquired Alfa Laval´s ART® reactors EMB is offering tailor made solutions for all kind of applications. More details at www.ehrfeld.com.

About Bayer Technology Services

Bayer Technology Services GmbH offers fully-integrated global solutions along the life cycle of chemical and pharmaceutical plants – from development through engineering and construction to process optimization for existing plants. The Bayer subsidiary employs 2,300 experts worldwide at its headquarters in Leverkusen and other German locations, as well as in regional offices in Belgium, Brazil, Canada, India, Mexico, Russia, Singapore, the United States and the People’s Republic of China. 2012 sales totaled approx. EUR 450 million.

Additional information about Bayer Technology Services at www.bayertechnology.com.

About Alfa Laval

Alfa Laval is a leading global provider of specialized products and engineering solutions based on its key technologies of heat transfer, separation and fluid handling. The company’s equipment, systems and services are dedicated to assisting customers in optimizing the performance of their processes. The solutions help them to heat, cool, separate and transport products in industries that produce food and beverages, chemicals and petrochemicals, pharmaceuticals, starch, sugar and ethanol. Alfa Laval’s products are also used in power plants, aboard ships, in the mechanical engineering industry, in the mining industry and for wastewater treatment, as well as for comfort climate and refrigeration applications. Alfa Laval’s worldwide organization works closely with customers in nearly 100 countries to help them stay ahead in the global arena.

Alfa Laval is listed on Nasdaq OMX, and, in 2012, posted annual sales of about SEK 29.8 billion (approx. 3.5 billion Euros). The company has today about 16 400 employees.

www.alfalaval.com.

For more information go to www.bayer.com

Forward-Looking Statements

This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual financial position, development or performance of the company and the estimates given here. These factors include those described in Bayer’s public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.